Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor β-gene

被引：0
|
作者：
Bastie, JN
Garcia, I
Terré, C
Cross, NCP
Mahon, FX
Castaigne, S
机构：
[1] Salisbury Dist Hosp, Dept Hematol & Oncol, Salisbury, Wilts, England
[2] Salisbury Dist Hosp, Dept Biochem Haematol & Cytogenet, Salisbury, Wilts, England
[3] Salisbury Dist Hosp, Wessex Reg Genet Lab, Salisbury, Wilts, England
[4] Univ Bordeaux 2, CNRS, Unite 2617, F-33076 Bordeaux, France
来源：
HAEMATOLOGICA | 2004年 / 89卷 / 10期
关键词：
atypical chronic myeloproliferative disorder; PDGFRB; t(5; 10); imatinib mesylate;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Imatinib mesylate has been reported to produce positive results in atypical chronic myeloproliferative disorders (CMD) with chromosomal translocations that disrupt the platelet-derived growth factor receptor (3 gene (PDGFRB). We used imatinib to treat a 49-year old man with atypical CMD in accelerated phase and the H4 (D10S170)-PDGFRB fusion gene. After 3 months of treatment, we observed grade 4 hematologic toxicity and a lack of response.
引用
收藏
页码：1263 / 1264
页数：2
相关论文
共 50 条
  • [31] THE PLATELET-DERIVED GROWTH-FACTOR RECEPTOR
    BOWENPOPE, DF
    ROSENFELD, ME
    SEIFERT, RA
    ROSS, R
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 1985, 26 (1-2) : 141 - 153
  • [32] Fibroblast Response to Gadolinium Role for Platelet-Derived Growth Factor Receptor
    Bhagavathula, Narasimharao
    Dame, Michael K.
    DaSilva, Marissa
    Jenkins, William
    Aslam, Muhammad N.
    Perone, Patricia
    Varani, James
    INVESTIGATIVE RADIOLOGY, 2010, 45 (12) : 769 - 777
  • [33] Expression of platelet-derived growth factor-AA and platelet-derived growth factor-α receptor in ameloblastomas
    Sulzbacher, Irene
    Wick, Nikolaus
    Pichlhofer, Bettina
    Mazal, Peter R.
    JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2008, 37 (04) : 235 - 240
  • [34] Role of platelet-derived growth factor in mesangium development and vasculopathies: lessons from platelet-derived growth factor and platelet-derived growth factor receptor mutations in mice
    Betsholtz, C
    Lindblom, P
    Bjarnegard, M
    Enge, M
    Gerhardt, H
    Lindahl, P
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2004, 13 (01): : 45 - 52
  • [35] Myeloproliferative neoplasm with basophilia and abnormality of platelet-derived growth factor receptor a translocation: a case report
    Choi, Jong Gwon
    Cho, Do Yeun
    BLOOD RESEARCH, 2022, 57 (01) : 69 - 74
  • [36] Inhibition of functional osteoblasts with the platelet-derived growth factor receptor (PDGFR) inhibitor imatinib mesylate in androgen-independent prostate cancer (PCa).
    Mathew, P
    Yang, J
    Kim, SJ
    Fidler, I
    Bucana, C
    Troncoso, P
    Wang, X
    Thall, P
    Logothetis, C
    Navone, N
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 413S - 413S
  • [37] Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor
    Rosenberg, Aaron
    Mathew, Paul
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (06) : 787 - 794
  • [38] Fusion of PRKG2 and SPTBN1 to the platelet-derived growth factor receptor beta gene (PDGFRB) in imatinib-responsive atypical myeloproliferative disorders
    Gallagher, Genevieve
    Horsman, Douglas E.
    Tsang, Peter
    Forrest, Donna L.
    CANCER GENETICS AND CYTOGENETICS, 2008, 181 (01) : 46 - 51
  • [39] PLATELET-DERIVED GROWTH-FACTOR IS DECREASED IN PATIENTS WITH MYELOPROLIFERATIVE DISORDERS
    KATOH, O
    KIMURA, A
    KURAMOTO, A
    AMERICAN JOURNAL OF HEMATOLOGY, 1988, 27 (04) : 276 - 280
  • [40] Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma
    Katayama, R
    Huelsmeyer, MK
    Marr, AK
    Kurzman, ID
    Thamm, DH
    Vail, DM
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 54 (01) : 25 - 33
12345